Recurrent gefitinib-induced interstitial lung disease.

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, treats non-small cell lung cancer.
• Interstitial lung disease (ILD) is a serious adverse effect associated with gefitinib treatment.
• Limited data exists on the safety of re-administering gefitinib after its discontinuation due to suspected drug-induced ILD.

Observation:

• A case of recurrent gefitinib-induced interstitial lung disease is presented.
• The patient experienced a second episode of ILD upon re-challenge with gefitinib.
• This recurrence highlights the potential risks of gefitinib re-administration.

Findings:

• Re-administration of gefitinib in patients with a history of gefitinib-induced ILD carries a significant risk of recurrence.
• The safety profile of gefitinib re-challenge in this context is not well-established.
• The case underscores the unpredictable nature of gefitinib-induced ILD.

Implications:

• Clinicians should exercise extreme caution when considering gefitinib re-administration in patients with a prior history of gefitinib-induced ILD.
• Alternative treatment options should be thoroughly explored before contemplating gefitinib re-challenge.
• Further research is needed to establish clear guidelines for managing gefitinib-induced ILD and its potential recurrence.